(A) Schematic of complement pathway and targets of currently approved complement inhibitors for PNH. PNH blood cells are deficient in CD55 and CD59, leading to complement dysregulation. Table of approved complement inhibitors in PNH. Drug half-life as listed in Food and Drug Administration labeling. (B) Change in hemoglobin from baseline with add-on danicopan to a C5 inhibitor in participants with clinically significant extravascular hemolysis in the phase 3 ALPHA trial. Dark blue bar indicates danicopan-danicopan group, green is placebo, and light blue is placebo-danicopan crossover arm. ∗All drugs are approved as single agents except danicopan, which is add-on therapy to eculizumab or ravulizumab. BID, twice a day; Hgb, hemoglobin; q, every; TID, 3 times a day.